BsUFA III Talks Could Move Cloud-Platform Goals Forward
Executive Summary
US FDA wants to use biosimilars for a demonstration of cloud-based technology, an idea mentioned to increase the use of real-time review and enhance data analysis.
You may also be interested in...
Califf: More Learning Necessary During Generic Drug Lifecycle
The US FDA commissioner called for enhancements to postmarketing data collection and analysis for generic drugs.
Real-World Evidence Under Consideration For Use In Interchangeable Biosimilar Applications
US FDA research funded under BSUFA III will investigate what kind of safety data is needed for interchangeability. A demonstration project aimed at improving biosimilar product development efficiency and enhanced regulatory decision-making also will be part of the new regulatory science research program.
Real-World Evidence Under Consideration For Use In Interchangeable Biosimilars Applications
US FDA research funded under BSUFA III will investigate what kind of safety data is needed for interchangeability. A demonstration project aimed at improving biosimilar product development efficiency and enhanced regulatory decision-making also will be part of the new regulatory science research program.